- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.02. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study | 232 | ACCESS Newswire | Proprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Petros Pharmaceuticals... ► Artikel lesen | |
| 21.02. | Petros Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.02. | Petros Pharmaceuticals announces pricing of $9.6 million public offering | 2 | Seeking Alpha | ||
| PETROS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 18.02. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants | 246 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter... ► Artikel lesen | |
| 11.02. | H.C. Wainwright raises Neurotrope stock target to $5 | 3 | Investing.com | ||
| 10.02. | Petros Pharmaceuticals, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 24.01. | Petros Pharmaceuticals files to sell units, no amount given | 1 | Seeking Alpha | ||
| 24.01. | Petros Pharmaceuticals, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 24.01. | Petros Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.01. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules | 276 | ACCESS Newswire | Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharmaceuticals... ► Artikel lesen | |
| 19.12.24 | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Featured in "New Era of Healthcare, AI, Data and Consumer Empowerment" | 276 | ACCESS Newswire | Company positions itself for new innovation utilizing AI and quantum computing to help expand patient access to drugs via OTC access NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Petros Pharmaceuticals... ► Artikel lesen | |
| 17.12.24 | Petros Pharmaceuticals, Inc.: Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually | 292 | ACCESS Newswire | Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK... ► Artikel lesen | |
| 16.12.24 | Petros Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.11.24 | Petros Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.24 | Petros Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 18.10.24 | Petros Pharmaceuticals adjusts executive's salary and terms | 2 | Investing.com | ||
| 18.10.24 | Petros Pharmaceuticals passt Gehalt und Vertragsbedingungen einer Führungskraft an | 1 | Investing.com Deutsch | ||
| 17.10.24 | Petros Pharmaceuticals ändert Bedingungen für Vorzugsaktien | 2 | Investing.com Deutsch | ||
| 17.10.24 | Petros Pharmaceuticals amends preferred stock terms | 2 | Investing.com | ||
| 17.10.24 | Petros Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 0,130 | -0,38 % | InnoCan Pharma: Großaktionär erhöht den Bestand auf über 20%?! | ||
| MPH HEALTH CARE | 23,800 | +0,85 % | MPH Health Care Aktie: Finanzberichte neutral bewertet | Der Gesundheitsinvestor MPH Health Care AG verzeichnete am 21. Februar 2025 einen marginalen Kursrückgang von 0,43 Prozent auf 23,20 EUR. Die Aktie des Berliner Unternehmens zeigt sich dennoch in einer... ► Artikel lesen | |
| CRESCO LABS | 0,800 | +1,78 % | Cresco Labs Inc. to Report Fourth Quarter 2024 Financial Results on March 12, 2025 Business Wire | ||
| QUANTUM BIOPHARMA | 4,220 | +2,93 % | Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302 | Safety Review Committee Found No Safety Concerns Following Milestone Trial TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma"... ► Artikel lesen | |
| CSPC PHARMA | 0,589 | +5,14 % | Die Aktie der CSPC Pharmaceutical Group läuft schlechter: Große Kursverluste! (0,582 €) | Zu den großen Verlierern am Aktienmarkt zählt heute die CSPC Pharmaceutical Group-Aktie . Der Titel verbilligt sich am Freitag deutlich. Mit einem Verlust von 5,52 Prozent gehört heute der Anteilsschein... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 7,460 | 0,00 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash | Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities... ► Artikel lesen | |
| AMARIN | 0,520 | +5,26 % | Amarin Corporation plc: Amarin Marks Key Milestone for VASCEPA/VAZKEPA (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol ... | -- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,794 | +3,25 % | Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata | SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA... ► Artikel lesen | |
| JAGUAR HEALTH | 0,570 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value | Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion diseaseFDA... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,872 | -3,11 % | XORTX initiiert Gichtprogramm und NDA-Gespräche mit der FDA | - Typ-C-Meeting ist Voraussetzung für
die Einleitung eines verkürzten NDA-Zulassungsverfahrens für XRx-026 zur Gichtbehandlung
CALGARY, AB - 24. Februar 2025 / IRW-Press... ► Artikel lesen | |
| NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA LR23: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNUMINUS WELLNESS... ► Artikel lesen | |
| CANNOVUM CANNABIS | 0,200 | -18,03 % | EQS-News: Cannovum Cannabis AG: Abwicklung bzw. Veräußerung der Beteiligungen im Cannabis-Bereich | EQS-News: Cannovum Cannabis AG
/ Schlagwort(e): Strategische Unternehmensentscheidung/Sonstiges
Cannovum Cannabis AG: Abwicklung bzw. Veräußerung der Beteiligungen im Cannabis-Bereich... ► Artikel lesen | |
| TALPHERA | 0,528 | +2,72 % | Talphera, Inc.: Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study | Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week
The FDA agreed to... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,060 | 0,00 % | BETTERLIFE HLDG (06909): DELAY IN DESPATCH OF CIRCULAR IN RELATION TO VERY SUBSTANTIAL ACQUISITIONS | ||
| MEDIPHARM LABS | 0,049 | -0,40 % | MediPharm to sell British Columbia cannabis facility to Rubicon for $4.5M |
Das Unternehmen PETROS PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,100 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PETROS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
